SELECTION OF PATIENTS WITH HEADACHE SUSCEPTIBLE TO ANTIBODIES AGAINST CALCITONIN GENE-RELATED PEPTIDE Russian patent published in 2022 - IPC A61K39/395 A61P25/06 

FIELD: pharmaceutics; medicine.

SUBSTANCE: first object is the use of an antibody or its antigen-binding fragment for the production of a drug for reduction in the frequency of headache attacks in a patient suffering from chronic or episodic migraine. In this case, the antibody or its antigen-binding fragment locks, inhibits, suppresses, or weakens a path with participation of calcitonin gene-related peptide (hereinafter – CGRP). Before the injection of the antibody or its antigen-binding fragment, it is known that the patient has allodynia and/or hyperalgesia during the acute phase of migraine, but not during the phase between migraine attacks. The second object is a method for the reduction in the frequency of migraine attacks in the above-mentioned patient, including the injection of the above-mentioned antibody or its antigen-binding fragment.

EFFECT: reduction in the frequency of headache attacks in a patient in the injection of an antibody or its antigen-binding fragment that lock, inhibit, suppress or weaken a path with the participation of CGRP, where, before the injection, it was determined or known that the patient has allodynia and/or hyperalgesia during the acute phase of migraine, but not during the phase between migraine attacks.

45 cl, 24 dwg, 6 tbl, 8 ex